# Low-dose Naltrexone for Post-COVID Fatigue Syndrome

> **NCT05430152** · PHASE2 · COMPLETED · sponsor: **Luis Nacul** · enrollment: 160 (actual)

## Conditions studied

- Post-Viral Fatigue Syndrome

## Interventions

- **DRUG:** Low-Dose Naltrexone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05430152
- **Lead sponsor:** Luis Nacul
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-15
- **Primary completion:** 2026-02-15
- **Final completion:** 2026-02-28
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430152, "Low-dose Naltrexone for Post-COVID Fatigue Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05430152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*